S-(-)-Carbidopa, >=98% (TLC), powder

S-(-)-Carbidopa, >=98% (TLC), powder

Biochem/physiol Actions

Peripheral inhibitor of L-aromatic amino acid decarboxylase. When co-administered with L-DOPA, it prevents extra-CNS conversion to dopamine, thereby increasing CNS concentrations of effective compounds. Selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells by increasing H2O2 in these cell lines, which are sensitive to reactive oxygen species.

General description

Carbidopa is used for treating restless legs (RL) syndrome and periodic leg movements in sleep (PLMS). Carbidopa along with levodopa is used to treat Parkinson?s disease.

Packaging

100 mg in glass bottle

25 mg in poly bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Quality Level InChI key InChI Manufacturer Solubility Form Assay Price Quantity
3577671 S-(-)-Carbidopa, >=98% (TLC), powder 200 TZFNLOMSOLWIDK-JTQLQIEISA-N 1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1 SIGMA-ALDRICH
£398.36 (exc VAT) per 100MG
-
+
3577672 S-(-)-Carbidopa, >=98% (TLC), powder 200 TZFNLOMSOLWIDK-JTQLQIEISA-N 1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1 SIGMA-ALDRICH
£132.88 (exc VAT) per 25MG
-
+